Neurocrine Biosciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | $1.10 | $1.10 | $1.10 |
| Q2 2024 | 5 | $1.13 | $1.13 | $1.13 |
| Q3 2024 | 5 | $1.50 | $1.53 | $1.52 |
| Q4 2024 | 12 | $1.35 | $1.95 | $1.61 |
| Q1 2025 | 5 | $1.17 | $1.64 | $1.40 |
| Q2 2025 | 4 | $1.48 | $1.58 | $1.53 |
| Q3 2025 | 4 | $1.60 | $1.71 | $1.64 |
| Q4 2025 | 4 | $1.86 | $1.99 | $1.91 |
| Q1 2026 | 3 | $2.03 | $2.17 | $2.09 |
| Q2 2026 | 3 | $2.33 | $2.49 | $2.39 |
| Q3 2026 | 3 | $2.47 | $2.64 | $2.54 |
| Q4 2026 | 3 | $2.66 | $2.84 | $2.74 |
Neurocrine Biosciences, Inc. Earnings Date And Information
Neurocrine Biosciences, Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $1.24 earnings per share for the quarter, missing analysts' consensus estimates of $1.51 by $0.27. The company had revenue of 622.10 M for the quarter and had revenue of 1.89 B for the year. Neurocrine Biosciences, Inc. has generated $3 earnings per share over the last year ($2.47 diluted earnings per share) and currently has a price-to-earnings ratio of 30.81. Neurocrine Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based on prior year's report dates.
Neurocrine Biosciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2024 | Q3 2024 | $1.51 | $1.28 | -0.23 | $600.64 M | $622.10 M |
| 08/01/2024 | Q2 2024 | $1.05 | $0.64 | -0.41 | $545.98 M | $590.20 M |
| 05/01/2024 | Q1 2024 | $1.01 | $0.43 | -0.58 | $515.30 M | |
| 02/09/2024 | Q4 2023 | $1.50 | $515.20 M | |||
| 10/31/2023 | Q3 2023 | $0.97 | $0.85 | -0.12 | $479.09 M | $498.80 M |
| 08/01/2023 | Q2 2023 | $0.78 | $0.98 | 0.2 | $447.34 M | $452.70 M |
| 05/03/2023 | Q1 2023 | $0.26 | -$0.79 | -1.05 | $420.40 M | |
| 02/09/2023 | Q4 2022 | $0.92 | $412.00 M | |||
| 11/01/2022 | Q3 2022 | $0.79 | $0.72 | -0.07 | $377.00 M | $387.90 M |
| 08/04/2022 | Q2 2022 | $0.56 | -$0.18 | -0.74 | $342.33 M | $378.20 M |
| 05/04/2022 | Q1 2022 | $0.35 | $0.15 | -0.2 | $310.60 M | |
| 02/11/2022 | Q4 2021 | $0.61 | -$0.08 | -0.69 | $312.00 M | |
| 11/01/2021 | Q3 2021 | $0.51 | $0.24 | -0.27 | $297.83 M | $296.00 M |
| 08/03/2021 | Q2 2021 | $0.48 | $0.45 | -0.03 | $273.19 M | $288.90 M |
| 05/05/2021 | Q1 2021 | $0.51 | $0.34 | -0.17 | $236.60 M | |
| 02/05/2021 | Q4 2020 | $3.72 | $247.90 M | |||
| 11/09/2020 | Q3 2020 | $0.11 | -$0.62 | -0.73 | $282.70 M | $258.50 M |
| 08/03/2020 | Q2 2020 | $0.73 | $0.86 | 0.13 | $261.31 M | $302.40 M |
| 05/06/2020 | Q1 2020 | $0.56 | $0.40 | -0.16 | $237.10 M | |
| 02/06/2020 | Q4 2019 | $0.37 | $244.10 M |
Neurocrine Biosciences, Inc. Earnings: Frequently Asked Questions
-
When is Neurocrine Biosciences, Inc.'s earnings date?
Neurocrine Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based off last year's report dates.
-
How can I listen to Neurocrine Biosciences, Inc.'s earnings conference call?
The conference call for Neurocrine Biosciences, Inc.'s latest earnings report can be listened to online.
-
How can I read Neurocrine Biosciences, Inc.'s conference call transcript?
The conference call transcript for Neurocrine Biosciences, Inc.'s latest earnings report can be read online.
-
How much revenue does Neurocrine Biosciences, Inc. generate each year?
Neurocrine Biosciences, Inc. (:NBIX) has a recorded annual revenue of $1.89 B.
-
How much profit does Neurocrine Biosciences, Inc. generate each year?
Neurocrine Biosciences, Inc. (:NBIX) has a recorded net income of $1.89 B. Neurocrine Biosciences, Inc. has generated $2.56 earnings per share over the last four quarters.
-
What is Neurocrine Biosciences, Inc.'s price-to-earnings ratio?
Neurocrine Biosciences, Inc. (:NBIX) has a price-to-earnings ratio of 30.81 and price/earnings-to-growth ratio is 2.45.
